Gilead Sciences Inc
Gilead Sciences Inc (GILD) Covered Calls
Gilead Sciences Inc trades in the Drug Manufacturers - General industry with an IV Rank of 65.08%, average versus the past year. GILD's highest covered call setup is the $180.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 7.09% out of the money with 7 days to expiration, a 7.12% return until expiration, and a 371.34% theoretical annualized return. Across the setups shown, annualized returns run from 156.99% to 371.34% at strikes between $172.50 and $200.00, with 7 to 41 days to expiration, as of Nov 13, 2026.
Read more
Running GILD covered calls helps you generate income from Gilead Sciences Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GILD covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If GILD stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GILD covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GILD covered call is worth writing.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
| 2026-11-20 | 7 | 180.00 | 7.09 | 0.05 | 0.29 | 1197.00 | 7.12 | 371.34 | -0.03 | +0.06 | 1,578 | 0.24 |
| 2026-11-20 | 7 | 177.50 | 5.60 | 0.17 | 0.52 | 959.00 | 5.71 | 297.51 | -0.10 | +0.10 | 173 | 0.35 |
| 2026-11-20 | 7 | 175.00 | 4.12 | 0.46 | 0.80 | 738.00 | 4.39 | 228.95 | -0.27 | +0.17 | 1,763 | 0.34 |
| 2026-11-27 | 14 | 182.50 | 8.58 | 0.08 | 0.71 | 1450.00 | 8.63 | 224.91 | -0.05 | +0.09 | 16 | 0.63 |
| 2026-12-18 | 35 | 200.00 | 18.99 | 0.04 | 0.50 | 3196.00 | 19.01 | 198.30 | -0.02 | +0.04 | 168 | 0.46 |
| 2026-11-27 | 14 | 180.00 | 7.09 | 0.09 | 0.83 | 1201.00 | 7.15 | 186.29 | -0.05 | +0.11 | 22 | 0.74 |
| 2026-12-11 | 28 | 190.00 | 13.04 | 0.16 | 0.88 | 2208.00 | 13.14 | 171.24 | -0.10 | +0.08 | 3 | 0.72 |
| 2026-12-18 | 35 | 195.00 | 16.02 | 0.40 | 0.61 | 2732.00 | 16.25 | 169.51 | -0.24 | +0.07 | 41 | 0.21 |
| 2026-11-20 | 7 | 172.50 | 2.63 | 0.97 | 1.29 | 539.00 | 3.21 | 167.21 | -0.58 | +0.27 | 309 | 0.32 |
| 2026-12-24 | 41 | 197.50 | 17.50 | 0.22 | 1.70 | 2964.00 | 17.63 | 156.99 | -0.13 | +0.11 | 0 | 1.48 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank65.08% Moderate
- Market cap (M$)207,856
- 52 weeks high-5.10%
- 52 weeks low43.38%
- Analyst recommendationBuy
1.61 - Target price$176.32
5.22% above the current stock price - Dividend—
- Payout ratio46.60%
- Earnings date2027-02-09
- P/E—
- Future P/E16.51
- EPS (ttm)-3.15
- EPS growth next 5 years9.68%
As of Nov 16, 2026